BioLineRx Ltd. (TLV:BLRX)
2.600
0.00 (0.00%)
Jul 24, 2025, 5:24 PM IDT
BioLineRx Employees
BioLineRx had 28 employees as of December 31, 2024. The number of employees decreased by 51 or -64.56% compared to the previous year.
Employees
28
Change (1Y)
-51
Growth (1Y)
-64.56%
Revenue / Employee
2.97M ILS
Profits / Employee
-451.87K ILS
Market Cap
63.94M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28 | -51 | -64.56% |
Dec 31, 2023 | 79 | 30 | 61.22% |
Dec 31, 2022 | 49 | 11 | 28.95% |
Dec 31, 2021 | 38 | 0 | - |
Dec 31, 2020 | 38 | -4 | -9.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Teva Pharmaceutical Industries | 35,686 |
Danel (Adir Yeoshua) | 4,290 |
Kamada | 420 |
Bait Bakfar | 227 |
SofWave Medical | 126 |
BrainsWay | 120 |
Novolog (Pharm-Up 1966) | 936 |
Ilex Medical | 178 |
BioLineRx News
- 2 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 2 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 2 months ago - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting - PRNewsWire
- 2 months ago - BioLineRx projects cash runway into H2 2026 while advancing PDAC pipeline and APHEXDA royalty growth - Seeking Alpha
- 2 months ago - BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioLineRx GAAP EPS of $0.00 beats by $0.95, revenue of $0.26M misses by $1.22M - Seeking Alpha
- 2 months ago - BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Earnings Scheduled For May 27, 2025 - Benzinga